Holen Sie sich die Stockscreener-App
1.55
3.33%
0.05
Vorhandelsmarkt:
1.55
Schlusskurs vom Vortag:
$1.50
Offen:
$1.51
24-Stunden-Volumen:
131.82K
Relative Volume:
0.37
Marktkapitalisierung:
$66.48M
Einnahmen:
$51.13M
Nettoeinkommen (Verlust:
$-93.80M
KGV:
-0.6951
EPS:
-2.23
Netto-Cashflow:
$-129.10M
1W Leistung:
+8.39%
1M Leistung:
+9.93%
6M Leistung:
+28.10%
1J Leistung:
-60.15%
1-Tages-Spanne:
$1.5005
$1.5622
1-Wochen-Bereich:
$1.50
$1.68
52-Wochen-Spanne:
$0.89
$4.22
Repare Therapeutics Inc Stock (RPTX) Company Profile
Firmenname
Repare Therapeutics Inc
Sektor
Branche
Telefon
(857) 412-7018
Adresse
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Vergleichen Sie RPTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.55 | 61.33M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-09 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-12 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-17 | Fortgesetzt | Goldman | Buy |
| 2021-09-23 | Eingeleitet | Stifel | Buy |
| 2021-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-03-01 | Eingeleitet | Berenberg | Buy |
| 2020-10-28 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-14 | Eingeleitet | Cowen | Outperform |
| 2020-07-14 | Eingeleitet | Goldman | Neutral |
| 2020-07-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Repare Therapeutics Inc Aktie (RPTX) Neueste Nachrichten
What analysts say about Repare Therapeutics Inc. stockRecord-breaking gains - jammulinksnews.com
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Access to Community - Newser
What drives Repare Therapeutics Inc. stock priceFree AI-Backed Trading Signals - jammulinksnews.com
Repare Therapeutics Inc. Stock Analysis and ForecastUnprecedented growth rates - jammulinksnews.com
Is Repare Therapeutics Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
what makes repare therapeutics inc. stock price move sharplyLow Risk Profit Ideas - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm - Yahoo Finance
How Repare Therapeutics Inc. stock performs during market volatilityBig Profit Small Risk Alerts - Newser
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Deb - GuruFocus
Repare Therapeutics Licenses Lunresertib to Debiopharm for Worldwide Development. - AInvest
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
Repare inks licensing deal with Debiopharm for lunresertib - The Pharma Letter
Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In - Stocktwits
how repare therapeutics inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Repare Therapeutics' Lunresertib Deal: A Strategic Pivot to Unlock Oncology Potential and Near-Term Catalysts - AInvest
Repare Therapeutics stock surges after $10M licensing deal with Debiopharm By Investing.com - Investing.com South Africa
What makes Repare Therapeutics Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser
Repare Therapeutics stock surges after $10M licensing deal with Debiopharm - Investing.com Nigeria
Repare Therapeutics Inc. Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - MarketScreener
Repare Therapeutics (RPTX) Secures Global Licensing Deal with Debiopharm | RPTX Stock News - GuruFocus
Repare Therapeutics enters exclusive worldwide licensing agreement with Debiopharm for Lunresertib - MarketScreener
Repare Therapeutics licenses PKMYT1 inhibitor to Debiopharm for $10 million - Investing.com Nigeria
Repare Therapeutics jumps on cancer drug licensing deal - TradingView
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib | RPTX Stock News - GuruFocus
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - Business Wire
Repare Therapeutics (NASDAQ:RPTX) Trading Down 4.9%What's Next? - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4.9% – Should You Sell? - Defense World
Repare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic Deal - Insider Monkey
Is Repare Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Repare Therapeutics Holds Annual Shareholder Meeting - TipRanks
Millennium Management LLC Acquires 67,638 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics (NASDAQ:RPTX) Shares Down 1.3%Here's Why - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Trading Down 1.3% – What’s Next? - Defense World
Finanzdaten der Repare Therapeutics Inc-Aktie (RPTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):